Skip to main content

Table 1 Baseline characteristics of the cohorts

From: Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study

 

All subjects n = 97

Normal mucosa (Marsh stage 0) n = 39

Lymphocytic enteritis (Marsh stage 1) n = 58

P

Demographic characteristics

    


Females, n (%)

86 (89)

34 (87)

52 (90)

0.959


Age in years, mean (SD)

50 (8)

49 (7)

51 (9)

0.222


BMI, kg/m2, mean (SD)

26 (4)

25 (3)

28 (5)

<0.001

Education level

    


None, n (%)

2 (2)

0

2 (3)

0.658


Primary education, n (%)

71 (73)

29 (74)

42 (72)

0.983


Secondary education, n (%)

22 (23)

10 (26)

12 (21)

0.746


Higher education, n (%)

3 (3)

0

2 (3)

0.658

Employment status

    


Employed, n (%)

45 (46)

21 (54)

24 (41)

0.317


Unemployed, n (%)

20 (21)

7 (18)

13 (22)

0.782


Homemaker, n (%)

17 (17)

8 (20)

9 (15)

0.717


Retired/pensioner, n (%)

15 (15)

3 (8)

12 (21)

0.147

First-degree relatives with CD/FMS

    


Subjects with CD relatives, n (%)

10 (10)

0

10 (17)

0.016


Subjects with FMS relatives, n (%)

4 (4)

0

4 (7)

0.248

Gastroduodenal histopathological details

    


IELs, mean (SD)

18 (3)

14 (2)

35 (5)

<0.001


Helicobacter pylori (+), n (%)

41 (42)

17 (43)

24 (41)

0.426

HLA haplotype

    


HLA-DQ2 A1/B1, n (%)

46 (47)

15 (38)

31 (53)

0.214


HLA-DQ2 (-), n (%)

15 (15)

4 (10)

11 (19)

0.381

Serum autoantibodies

    


Anti tTG-2, U/ml, mean (SD)

0.7 (0.6)

0.5 (0.1)

0.9 (0.7)

<0.001


RF, IU/m, mean (SD)

12.8 (1.7)

12.6 (0.9)

12.9 (2.1)

0.552


Anti-TPO (+), U/ml, mean (SD)

30 (111)

20 (30)

51 (140)

0.115


ANAs (+), n (%)

26 (27)

3 (8)

23 (40)

0.001


AMAS (+), n (%)

4 (4)

0

4 (7)

0.248

  1. Data are expressed as frequency (n) and percentage of the total value (%), or mean and standard deviation (SD). BMI, body mass index; IELs, intraepithelial lymphocyte count from 100 epithelial cells; anti-tTG-2, anti-tissue transglutaminase-2 antibodies; RF, rheumatoid factor; HLA-DQ2, major histocompatibility complex class II; anti-TPO, anti-thyroid peroxidase antibodies; ANAs, anti-nuclear antibodies; AMAs, anti-mitochondrial antibodies.